HERMIONE: A randomized Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician's choice plus trastuzumab in patients with previously treated, anthracycline-naïve, HER2-positive, locally advanced/metastatic breast cancer

  1. Miller, K.
  2. Cortes, J.
  3. Hurvitz, S.A.
  4. Krop, I.E.
  5. Tripathy, D.
  6. Verma, S.
  7. Riahi, K.
  8. Reynolds, J.G.
  9. Wickham, T.J.
  10. Molnar, I.
  11. Yardley, D.A.
Aldizkaria:
BMC Cancer

ISSN: 1471-2407

Argitalpen urtea: 2016

Alea: 16

Zenbakia: 1

Mota: Artikulua

DOI: 10.1186/S12885-016-2385-Z GOOGLE SCHOLAR lock_openSarbide irekia editor
Datuen iturria: Scopus